- /
- Supported exchanges
- / US
- / ENGN.NASDAQ
enGene Holdings Inc. Common Stock (ENGN NASDAQ) stock market data APIs
enGene Holdings Inc. Common Stock Financial Data Overview
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get enGene Holdings Inc. Common Stock data using free add-ons & libraries
Get enGene Holdings Inc. Common Stock Fundamental Data
enGene Holdings Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -127 141 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get enGene Holdings Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-03-09
- EPS/Forecast: -0.5738
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Holdings Inc. Common Stock News
New
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Omega Fund Management cut its stake in Kestra Medical Technologies (NASDAQ:KMTS), selling 351,442 shares in the first quarter for an estimated $8.28 million based on quarterly average pricing, accordi...
Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink Partners lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $...
Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios
We just covered the 14 Best Defensive Stocks to Invest In Now and Bristol-Myers Squibb Company (NYSE:BMY) ranks 5th on this list. Bristol-Myers Squibb Company (NYSE:BMY) remains a favorite for conser...
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.